Skip to main content
SpringerLink
Log in

Von einfach bis flexibel — zur Auswahl stehen drei Strategien

Insulintherapie bei Typ-2-Diabetes

  • FORTBILDUNG
  • ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Jeder dritte Typ-2-Diabetiker braucht Insulin. Nun haben Sie die Wahl zwischen basaler Insulintherapie, Mischinsulintherapie und prandialer Insulintherapie. Bei der Therapieentscheidung ist natürlich die optimale Blutzuckereinstellung, aber auch die Fähigkeiten und Vorstellungen der Patienten zu berücksichtigen. Mehr dazu erfahren Sie im folgenden Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Ray KK, Seshasai SR, Wijesuriya S et al. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 373: 1765–1772

    Article  PubMed  CAS  Google Scholar 

  2. Guideline for Management of Post Meal Glucose in Diabetes. International Diabetes Federation (IDF), Brussels, 2011

  3. Wright A, Burden AC, Paisey RB et al. (2002) Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25: 330–336

    Article  PubMed  CAS  Google Scholar 

  4. Mitrakou A, Kelley D, Mokan M et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22–29

    Article  PubMed  CAS  Google Scholar 

  5. Liebl A (2008) Differenzierte Insulintherapie des Typ-2-Diabetes. Diabetologe 4:516–524

    Article  Google Scholar 

  6. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617–621

    Google Scholar 

  7. Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26: 881–885

    Article  PubMed  Google Scholar 

  8. Heise T, Nosek L, Ronn BB et al. (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53: 1614–1620

    Article  PubMed  CAS  Google Scholar 

  9. Bretzel RG, Nuber U, Landgraf W et al. (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073–1084

    Article  PubMed  CAS  Google Scholar 

  10. Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080–3086

    Article  PubMed  CAS  Google Scholar 

  11. Hermansen K, Davies M, Derezinski T et al. (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29: 1269–1274

    Article  PubMed  CAS  Google Scholar 

  12. Klein O, Lynge J, Endahl L et al. (2006) Insulin Detemir and Insulin Glargine: Similar Time-Action Profiles in Subjects with Type 2 Diabetes. Diabetes Care 55: A76

    Google Scholar 

  13. Blonde L, Merilainen M, Karwe V, Raskin P (2009) Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets — the TITRATE study. Diabetes Obes Metab 11: 623–631

    Article  PubMed  CAS  Google Scholar 

  14. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B (2009) Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 11:45–52

    Article  PubMed  CAS  Google Scholar 

  15. Garber AJ, Wahlen J, Wahl T et al. (2006) Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes. Obes Metab 8: 58–66

    Article  PubMed  CAS  Google Scholar 

  16. Garber AJ (2006) Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 66: 31–49

    Article  PubMed  CAS  Google Scholar 

  17. Kurtzhals P, Schaffer L, Sorensen A et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005

    Article  PubMed  CAS  Google Scholar 

  18. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK (2009) Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. N Engl J Med 361;18: 1736–1747

    Article  PubMed  CAS  Google Scholar 

  19. Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M. (2008) Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 31(7):1305–10.

    Article  PubMed  CAS  Google Scholar 

  20. Goudswaard AN, Furlong NJ, Rutten GE et al. (2004) Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev: CD003418

  21. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes- und Stoffwechselzentrum, m&i-Fachklinik Bad Heilbrunn, Wörnerweg 30, D-83670, Bad Heilbrunn, Deutschland

    Andreas Liebl

Authors
  1. Andreas Liebl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Liebl.

Additional information

Interessenkonflikt

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Er legt folgende potenzielle Interessenkonflikte offen: Vortragstätigkeit, Mitwirkung in Advisory Boards, Unterstützung für wissenschaftliche Projekte durch Berlin-Chemie, Lilly, Novo Nordisk, Sanofi-Aventis, AstraZeneca, MSD, Roche, Medtronic.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liebl, A. Von einfach bis flexibel — zur Auswahl stehen drei Strategien. MMW - Fortschritte der Medizin 154, 66–74 (2012). https://doi.org/10.1007/s15006-012-1298-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-012-1298-2

Keywords - Insulin therapy of typ 2 diabetes: From simple to flexible — three strategies are available

Search

Navigation